ETC

Recommend
Index
  • Aggrastat®

    Aggrastat®

    Ingredient

    Each mL contains Tirofiban Hydrochloride Monohydrate-0.281mg (as Tirofiban
    0.25mg)

    Content

    0.25mg/mL

    Indication

    AGGRASTAT, in combination with heparin,
    is indicated for the treatment of acute coronary syndrome, including patients
    who are to be managed medically and those undergoing percutaneous transluminal
    coronary angioplasty (PTCA) or atherectomy. In this setting, AGGRASTAT has been
    shown to decrease the rate of a combined endpoint of death, new myocardial
    infarction or refractory ischemia/repeat cardiac procedure.

  • Allegra tablet  30mg

    Allegra tablet 30mg

    Ingredient

    fexofenadine hydrochloride

    Content

    30mg

    Indication

    Relief of symptoms associated with seasonal allergic rhinitis and  allergic dermatitis (chronic idiopathic urticaria) in children 6-11 years of age.

  • Allegra tablet 120mg

    Allegra tablet 120mg

    Ingredient

    120mg

    Content

    120mg

    Indication

    Relief of symptoms associated with allergic rhinitis in adults and children 12 years of age and older.

  • Allegra® tablet 180mg

    Allegra® tablet 180mg

    Ingredient

    fexofenadine hydrochloride

    Content

    180mg

    Indication

    Relief of symptoms associated with allergic skin disease(chronic idiopathic urticarcia) in adults and children 12 years of age and older

  • Amaryl M tablet

    Amaryl M tablet

    Ingredient

    1/250mg : glimepiride 1mg, metformin hydrochloride 250mg
    2/500mg : glimepiride 2mg, metformin hydrochloride 500mg
    1/500mg : glimepiride 1mg, metformin hydrochloride 500mg

    Content

    1/250mg, 2/500mg, 1/500mg

    Indication

    As an adjunct to diet and exercise in NIDDM (type 2) patients

    – In case that the monotherapy with sulfonylurea or metformin does not result in adequate glycemic control

    – Replacement of combination therapy of sulfonylurea and metformin

  • Amaryl Mex tablet

    Amaryl Mex tablet

    Ingredient

    glimepiride/metformin hydrochloride

    Content

    2mg/500mg

    Indication

    As an adjunct to diet and exercise in NIDDM (type 2) patients

    – In case that the monotherapy with sulfonylurea or metformin does not result in adequate glycemic control

    – Replacement of combination therapy of sulfonylurea and metformin

  • Amaryl tablet

    Amaryl tablet

    Ingredient

    glimepiride

    Content

    1mg/2mg/4mg

    Indication

    Treatment of type II diabetics

  • Arixtra® Injection (Pre-filled)

    Arixtra® Injection (Pre-filled)

    Ingredient

    Each pre-filled syringe (0.5 ml) contains 2.5 mg of fondaparinux sodium

    Content

    2.5mg/pre-filled syringe(0.5mL)

    Indication

    1. Prevention of Venous Thromboembolic Events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery.
    2. Prevention of Venous Thromboembolic Events (VTE) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery
    3. Prevention of Venous Thromboembolic Events (VTE) in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease.
    4. Treatment in patients with UA/NSTEMI (Unstable Angina/Non-ST-segment Elevation Myocardial Infarction) not undergoing PCI

    5. Treatment in patients with STEMI (ST-segment Elevation Myocardial Infarction) either treated with thrombolytic drugs or not undergoing reperfusion therapy

  • Calcort® tablet

    Calcort® tablet

    Ingredient

    Deflazacort

    Content

    6mg

    Indication

    – Rheumatic disorders and collagen disease
    – Dermatologic disorders
    – Allergic conditions
    – Pulmonary disease
    – Disease of the eye
    – Hematopoietic disease
    – Gastrointestinal and liver disease
    – Kidney disease

  • Claforan injection

    Claforan injection

    Ingredient

    cefotaxime sodium

    Content

    0.5g, 1.0g

    Indication

    Infections of the


    – Respiratory tract(tonsilitis, pneumonia, pulmonary abscess, etc)


    – kidneys and urinary tract (pyelonephritis, cystitis, urethritis, prostatitis, etc


    – skin and soft tissues(wound, burn, cellulitis, etc)


    – Bones and joints (osteomyelitis, septic arthritis)


    – Genital organs (gonorrhea, intrauterine, parametritis, etc)


    – abdominal region(peritonitis, cholangitis, cholecystitis, etc)

TOP